secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001558370-22-015497
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines
--------------------------------------------------------------------------------

- BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.
- Program valued up to $25M over 5 years for SuVax Phase 1 studies, with options for MarVax.
- SuVax demonstrated 100% protection in non-human primate model with 3-dose series.
- No protective vaccines currently available for Sudan ebolavirus or Marburg marburgvirus.
- Contract award not guaranteed; requires favorable technical review and negotiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/0001558370-22-015497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/tmb-20221027x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer